Abstract
The artificial liver support system (ALSS) was first applied to treat acute liver failure in the 1970s with an attempt to replace the detoxification functions of the liver. In the past five decades, a variety of different types of ALSS have been developed to bridge patients with liver failure (LF) to liver transplantation or to support the failing liver temporarily, until it is able to regenerate. It has been demonstrated that some types of ALSS, such as plasma exchange (PE) and plasma bilirubin adsorption (PBA), are able to remove toxic substances, improve coagulopathy, and prevent bleeding. How to take the application of ALSS to bridge LF patients to liver transplantation has become a challenge? In this chapter, we summarized the role of ALSS played in perioperative period of liver transplantation patients.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
Park MS, Lee KW, Suh SW, et al. Living-donor liver transplantation associated with higher incidence of hepatocellular carcinoma recurrence than deceased-donor liver transplantation. Transplantation. 2014;97:71–7.
Watashi K, Sluder A, Daito T, et al. Cyclosporin A and its analogs inhibit hepatitis B virus entry into cultured hepatocytes through targeting a membrane transporter, sodium taurocholate cotransporting polypeptide (NTCP). Hepatology. 2014;59:1726–37.
Clavien PA, Lesurtel M, Bossuyt PM, et al. Recommendations for liver transplantation for hepatocellular carcinoma: an international consensus conference report. Lancet Oncol. 2012;13:e11–22.
Gosalia AJ, Martin P, Jones PD. Advances and future directions in the treatment of hepatocellular carcinoma. Gastroenterol Hepatol. 2017;13:398–410.
Bhangui P, Vibert E, Ma**o P. Intention-to-treat analysis of liver transplantation for hepatocellular carcinoma: living versus deceased donor transplantation. Hepatology. 2011;53:1570–9.
Hammad A, Kaido T, Ogawa K, et al. Liver transplantation for advanced hepatocellular carcinoma in patients with child-Pugh A and B. Surg Today. 2016;46:248–54.
Ninomiya M, Shirabe K, Facciuto ME, et al. Comparative study of living and deceased donor liver transplantation as a treatment for hepatocellular carcinoma. J Am Coll Surg. 2015;220:297–304.
Le Moine O, Louis O, Demols A, et al. Cold liver ischemia-reperfusion injury critically depends on liver T cells and is improved by donor pretreatment with interleukin 10 in mice. Hepatology. 2000;31:1266–74.
Fukazawa K, Lang JD. Role of nitric oxide in liver transplantation: should it be routinely used? World J Hepatol. 2016;8:1489–96.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2021 Springer Nature Singapore Pte Ltd. and Zhejiang University Press
About this chapter
Cite this chapter
Chen, D., Shen, T., Wu, J. (2021). Artificial Liver and Liver Transplantation. In: Li, L. (eds) Artificial Liver. Springer, Singapore. https://doi.org/10.1007/978-981-15-5984-6_20
Download citation
DOI: https://doi.org/10.1007/978-981-15-5984-6_20
Published:
Publisher Name: Springer, Singapore
Print ISBN: 978-981-15-5983-9
Online ISBN: 978-981-15-5984-6
eBook Packages: MedicineMedicine (R0)